Status:
COMPLETED
Impact of Hyperoncotic Albumin to Support Blood Loss Replacement
Lead Sponsor:
Insel Gruppe AG, University Hospital Bern
Conditions:
Blood Loss, Surgical
Fluid Retention
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
Fluid treatment is usually performed with either balanced crystalloid fluids or iso-oncotic colloids, (synthetic colloids, plasma and 5% albumin). Doubts have been raised about synthetic colloids (imp...
Detailed Description
Bladder cancer occurs mainly in old comorbid patients. The standard treatment of localized muscle invasive bladder cancer is pelvic lymph node dissection and open radical cystectomy with urinary diver...
Eligibility Criteria
Inclusion
- Non emergent radical cystectomy with urinary diversion
- Adult: older than 18 years
- Written informed consent
Exclusion
- Significant renal dysfunction: glomerular filtration rate \< 60 ml/min/1,73 m² (Kidney Disease Outcomes Quality Initiative stage 3 or more )
- History of heart failure
- Contraindications to the class of drugs under study, e.g. known hypersensitivity or allergy to class of drugs or the investigational product,
- Women who are pregnant or breast feeding (exclusion of surgery per se)
- Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc. of the participant,
- Enrolment of the investigator, his/her family members, employees and other dependent persons
Key Trial Info
Start Date :
March 18 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 18 2020
Estimated Enrollment :
24 Patients enrolled
Trial Details
Trial ID
NCT03848507
Start Date
March 18 2019
End Date
February 18 2020
Last Update
February 20 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Patrick Wuethrich, Department of Anaesthesiology and Pain Therapy, University Hospital Bern Inselspital Bern
Bern, Canton of Bern, Switzerland, 3010